Medical affairs teams are important for achieving regulatory compliance and maximizing productivity and communication by providing accurate disease information to internal teams, consumers and HCPs. Additionally, they help maintain relationships with KOLs and work with clinical and commercial groups to ensure clinical data is understood and used accurately in commercial operations. Essentially, they constitute the backbone for successful product launches and postmarket activities. Nevertheless, medical affairs’ roles and responsibilities can vary greatly depending on the company’s life cycle and whether a company has prelaunch vs. mature products or is undergoing a merger and/or acquisition.
Among many key topics, the 8th Medical Affairs Executive Forum addresses how medical affairs departments are affected by the current pharmaceutical landscape, including the impact of a company’s product life cycle on medical affairs functions, ways to use innovation in medical affairs to overcome challenges and move from R&D to commercialization, how to demonstrate the value of HEOR to payers, strategies to successfully establish a medical affairs launch readiness plan, and — most importantly — how to strengthen and optimize the role of medical affairs across all company verticals.
This conference is designed for representatives from pharmaceutical, biotechnology and medical device organizations with responsibilities in the following areas: